Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
38.50%
Operating Margin
32.65%
Net Margin
25.20%
Efficiency Metrics
Revenue per Expense Ratio
1.48
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
45.77%
Income Tax Rate
0.12%
EPS
0.4700000000
Balance Sheet Analysis
Current Ratio
1.55
Cash Ratio
0.47
Working Capital
$38.43M
Debt to Equity
0.56
Debt to Assets
34.30%
Equity Ratio
61.23%
Cash Flow Analysis
Operating Cash Flow Ratio
35.60%
Free Cash Flow Ratio
16.79%
CapEx to Revenue
18.81%
Dividends Paid
$89.78M
Stock Buybacks
No buybacks
Total Shareholder Returns
$89.78M
Cash Position Change
-47.30%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 283.01%
Detailed Growth Metrics
Core Performance
Revenue
15.43%
Net Income
553.67%
EPS
528.34%
Operating Income
205.47%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
21.77%
Operating Cash Flow
477.79%
Free Cash Flow
192.27%
Balance Sheet Health
Assets
-0.17%
Debt
-1.45%
Book Value per Share
-3.54%
Inventory
66.58%
Shareholder Returns
Dividends per Share
283.01%
Shares Outstanding
3.35%
Long Term Trends
3Y Revenue/Share
-21.02%
5Y Revenue/Share
-7.87%
3Y Dividend/Share
-4.53%
5Y Dividend/Share
514.31%